Alkermes (NASDAQ:ALKS – Get Free Report) released its quarterly earnings data on Wednesday. The company reported $0.43 earnings per share for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.15), Briefing.com reports. Alkermes had a net margin of 25.17% and a return on equity of 20.31%. The company had revenue of $350.37 million for the quarter, compared to analysts’ expectations of $360.26 million. During the same quarter in the previous year, the business posted ($0.10) EPS. The business’s quarterly revenue was up 21.8% on a year-over-year basis. Alkermes updated its FY 2024 guidance to 2.800-2.800 EPS.
Alkermes Trading Up 0.8 %
Shares of Alkermes stock opened at $24.05 on Friday. The company has a current ratio of 3.13, a quick ratio of 2.50 and a debt-to-equity ratio of 0.23. Alkermes has a twelve month low of $22.01 and a twelve month high of $33.71. The firm has a market capitalization of $4.07 billion, a PE ratio of 9.51, a P/E/G ratio of 0.66 and a beta of 0.61. The firm’s 50-day moving average price is $26.73 and its 200 day moving average price is $26.74.
Insiders Place Their Bets
In other news, SVP Christian Todd Nichols sold 10,417 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $28.10, for a total value of $292,717.70. Following the transaction, the senior vice president now owns 65,911 shares in the company, valued at $1,852,099.10. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.76% of the stock is owned by company insiders.
Analyst Ratings Changes
ALKS has been the subject of a number of analyst reports. TheStreet raised Alkermes from a “c+” rating to a “b” rating in a report on Thursday, February 15th. StockNews.com cut shares of Alkermes from a “buy” rating to a “hold” rating in a research note on Friday. Robert W. Baird assumed coverage on shares of Alkermes in a research report on Tuesday, March 19th. They set an “outperform” rating and a $37.00 price target on the stock. Jefferies Financial Group upped their price objective on shares of Alkermes from $42.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, April 9th. Finally, UBS Group lowered shares of Alkermes from a “neutral” rating to a “sell” rating and set a $25.00 target price on the stock. in a research note on Tuesday, February 20th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $35.38.
Read Our Latest Report on ALKS
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Featured Articles
- Five stocks we like better than Alkermes
- Options Trading – Understanding Strike Price
- MarketBeat Week in Review – 4/29 – 5/3
- How to buy stock: A step-by-step guide for beginners
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Transportation Stocks Investing
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.